Treating Diabetes with Actos and Risk of Bladder Cancer

Mr. Fromson is a Partner with Finkelstein & Partners, LLP, and he participates in the firm’s litigation involving dangerous drugs.

Being a diabetic is tough enough and monitoring your blood sugar just got tougher.  Users of the drug, Actos, who already have to confront its association with heart failure, now confront another concern:  bladder cancer.  And those patients who have suffered bladder cancer while ingesting Actos, and other pioglitazone-containing medicines, are inquiring whether the makers of Actos adequately warned of the bladder cancer risk. Last week, the U.S. Food and Drug Administration (FDA),  approved updated drug labels for pioglitazone-containing medicines to include safety information that the use of pioglitazone may be associated with an increased risk of bladder cancer.  The active ingredient in Actos, Pioglitazone, is also used in ActoPlus met, ActoPlus met XR and Duetac to treat Type 2 Diabetes.  The updated drug labels recommend that healthcare professionals should not use pioglitazone in patients with active bladder cancer and that pioglitazone should be used with caution in patients with a prior history of bladder cancer.  This labeling revision follows on the heels of FDA’s June 2011 Drug Safety Communication where FDA indicated that ACTOS use of more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer. The ACTOS product labeling as of 2011 did not inform as to a causal relationship with bladder cancer.  Rather, after summarizing animal studies with rats, as well as two 3-year trials in which ACTOS was compared to placebo or glyburide, the labeling stated there were too few events of bladder cancer to establish causality.   Although the occurrence of such cancers in animal test subjects during pre-market studies was well know to regulatory agencies and the manufacturer, Takeda, Inc., the drug Actos, as well various combination therapy regiments that incorporate Actos, have been used to treat Type 2 Diabetes since 2000, without warning of a causal relationship of the drug to bladder cancer.  According to the FDA, over 2.3 million prescriptions for the drug were issued in the United States in 2010. The drug manufacturer (Takeda) is now sponsoring long term studies regarding patients with diabetes who are members of Kaiser Permanente Northern California (KPNC) health plan.  But a shorter five-year analysis (1997 – 2008)  of pioglitazone exposure longer than 12 months, compared to never being exposed to pioglitazone, was associated with a 40% increased risk of bladder cancer.  In 2010,  a case control study in the Journal, Cancer, discussed the increased risk while also recognizing the already existing association between bladder cancer incidence and diabetes, wherein it stated “Our findings support an association between bladder cancer incidence and diabetes, and further suggest that the risk may be greater among patients taking oral hypoglycemics and those with diabetes of longer duration.” Cancer 2010. © 2010 American Cancer Society.  Earlier this year, the European Medicines Agency (EMA) — Europe’s equivalent of the FDA — announced that France had already pulled from pharmacy shelves pioglitazone-containing medicines (Actos, Competact).  The EMA announcement indicated “[t]his decision by the French authority follows receipt of results of a retrospective cohort study carried out in France which became available today. These results appear to suggest an increased risk of bladder cancer with pioglitazone.” Determining whether ACTOS or other pioglitazone-containing medicines contributed to an individual’s bladder cancer requires a case-sensitive in depth review of medical history.   Individuals who smoke are at greater risk for bladder cancer, and so are people who have  exposure to toxic chemicals such as arsenic, phenols, aniline dyes, and arylamines.  Dye workers, rubber workers, aluminum workers, leather workers, truck drivers, and pesticide applicators may be at a higher risk, too.  Also, long-term chronic infections of the bladder, irritation due to stones or foreign bodies are some other factors which predispose individuals to bladder cancer. If you or anyone you know has been diagnosed with bladder cancer and was prescribed Actos, ActoPlus met, ActoPlus met XR or Duetac (Pioglitazone) to treat Type 2 Diabetes, contact Finkelstein & Partners, LLP, for a free evaluation of your case.

Dear Friends and Clients,

In furtherance of our firm’s culture of commitment to always act with compassion, concern and commitment to our clients, community and colleagues, we have been taking precautions to ensure that we are still fulfilling our ethical and moral obligations while prioritizing health, wellness and safety of all we can.

As you know, the COVID-19 pandemic has introduced changes to many lives and businesses in our communities, and around the world. We, much like our neighbors and friends, have been taking precautions to ensure that we are still fulfilling our ethical and moral obligation to our clients, while also prioritizing the health, wellness and safety of our employees.

Until further notice, our offices will be closed to the public to encourage social distancing and to help prevent the spread of COVID-19. Our team is still hard at work, many from home, and you may still call, email, live chat or video conference us if you or a loved one is seeking legal assistance. As the first law firm to offer our clients secure online access to their case file more than a decade ago, we have always been believers in using technology to make life easier and information more accessible. In these present times it has been a smooth transition for us to continue to offer our clients the same seamless and thorough service that you deserve and are accustomed to.

This pandemic is unlike anything any of us have faced in our lifetimes, and while we can continue to emotionally support one another through it all, staying home and keeping your distance is vital to the health and wellness of our communities. It does not feel good to break routines, cancel events and retreat from our normal, day-to-day socializing, but let us remember that, in times of strife, prior generations were asked to go to war and we are simply being asked to stay home. Your isolation equals more lives saved, and more time for medical providers to prepare for the treatment of patients battling COVID-19.

When the dust settles, we will join together with a greater appreciation for our lives, local businesses, loved ones and health. Until then, we will continue to offer guidance from a safe distance.

Very truly yours,

Andrew G. Finkelstein and the staff of Finkelstein & Partners, LLP